drugset / Trial / NCT01181921

The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

NCT01181921

Phase 4 Terminated 1 enrolled Janssen-Cilag, S.A.
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the modulating effect of galantamine on circadian rhythm in patients with moderate Alzheimer's disease.

Timeline

Start
2011-05
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Galantamine Small molecule 16 mg Oral
Subject Galantamine Small molecule 24 mg Oral

Indications